title: Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.
abstract: In an international collaborative study, a central histologic review identified 891 patients with essential thrombocythemia, strictly defined by World Health Organization criteria. After a median follow-up of 6.2 years, 109 (12%) patients experienced arterial (n = 79) or venous (n = 37) thrombosis. In multivariable analysis, predictors of arterial thrombosis included age more than 60 years (P = .03; hazard ratio [HR] = 1.7), thrombosis history (P = .003; HR = 2.1), cardiovascular risk factors including tobacco use, hypertension, or diabetes mellitus (P = .007; HR = 1.9), leukocytosis (> 11 × 10(9)/L; P = .04; HR = 1.7), and presence of JAK2V617F (P = .009; HR = 2.6). In contrast, only male gender predicted venous thrombosis. Platelet count more than 1000 × 10(9)/L was associated with a lower risk of arterial thrombosis (P = .007; HR = 0.4). These associations, except the one with leukocytosis, remained significant (or near significant) when analysis was restricted to JAK2V617F-positive cases. The current study clarifies the contribution of specific disease and host characteristics to the risk of arterial versus venous thrombosis in essential thrombocythemia.
authors.affiliation: Ospedali Riuniti di Bergamo, Largo Barozzi 1, Bergamo, Italy.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Carobbio
authors.forename: Juergen
authors.initials: J
authors.lastname: Thiele
authors.forename: Francesco
authors.initials: F
authors.lastname: Passamonti
authors.forename: Elisa
authors.initials: E
authors.lastname: Rumi
authors.forename: Marco
authors.initials: M
authors.lastname: Ruggeri
authors.forename: Francesco
authors.initials: F
authors.lastname: Rodeghiero
authors.forename: Maria Luigia
authors.initials: ML
authors.lastname: Randi
authors.forename: Irene
authors.initials: I
authors.lastname: Bertozzi
authors.forename: Alessandro M
authors.initials: AM
authors.lastname: Vannucchi
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Antonioli
authors.forename: Heinz
authors.initials: H
authors.lastname: Gisslinger
authors.forename: Veronika
authors.initials: V
authors.lastname: Buxhofer-Ausch
authors.forename: Guido
authors.initials: G
authors.lastname: Finazzi
authors.forename: Naseema
authors.initials: N
authors.lastname: Gangat
authors.forename: Ayalew
authors.initials: A
authors.lastname: Tefferi
authors.forename: Tiziano
authors.initials: T
authors.lastname: Barbui
mesh_terms: D001158:Arteries / Q000473:pathology*; D002318:Cardiovascular Diseases / Q000150:complications; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000150:complications; D015994:Incidence; D007390:International Agencies; D053614:Janus Kinase 2 / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D011087:Polycythemia Vera / Q000150:complications; D011379:Prognosis; D012307:Risk Factors; D015996:Survival Rate; D013920:Thrombocythemia, Essential / Q000150:complications* / Q000628:therapy; D013927:Thrombosis / Q000209:etiology* / Q000473:pathology; D020246:Venous Thrombosis / Q000209:etiology* / Q000473:pathology
chemical_list: C507924:JAK2 protein, human; D053614:Janus Kinase 2